glofitamab,ipilimumab
bms,roche
['dlbcl', 'glofitamab', ' ipi ']
glofitamab + rchop in untreated dlbcl: n= 56; stage 3-4 96%, bulky disease 34%, high ipi 60%. eot cr 72.7%, orr 83.6%. high responses were noted across all ipi, no major ae and dose reductions were observed. crs 10.7%, grade 3 neutropenia 41.1%. #ash22